|
|
Article: Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study.(Clinical report)
- Article from:
- Heart Disease Weekly
- Article date:
- September 21, 2008
CopyrightCOPYRIGHT 2008 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Biosensors International Group, Ltd ("Biosensors", "Company"), (Bloomberg: BIG:SP), (Singapore:B20) announced that a next-generation drug-eluting stent, developed by Biosensors, has demonstrated equal safety and efficacy as compared to Johnson & Johnson's industry leading drug-eluting stent, CYPHER SELECT(TM) ("Cypher"), based upon nine-month clinical and angiographic follow-up data. The results of the landmark study were presented today at the 2008 European Society of Cardiology Congress and published concurrently on-line by the prestigious UK medical journal The Lancet (see also Biosensors International Group, Ltd).
LEADERS (Limus Eluted from A Durable versus ...